Protein kinase C (PKC) regulates keratinocyte growth and differentiation as well as
inflammation in skin, processes which are abnormal in
skin diseases such as
psoriasis. 12-O-tetradecanoylphorbol-13-acetate (TPA) binds to and activates PKC. We investigated the effects of
SCH 47112, a novel
staurosporine derivative, which interacts with the catalytic domain of PKC, on TPA-induced
inflammation and
hyperplasia in hairless mouse skin and TPA-induced differentiation in cultured human keratinocytes. Dorsal mouse skin was treated with vehicle, TPA (2.0/ 2.5 nmol) or
SCH 47112 followed by TPA. Epidermal thickness, and epidermal, upper dermal and deep dermal
inflammation (assessed on an ordinal semiquantitative scale) were determined in biopsies taken 24 h and 48 h post-treatment.
SCH 47112 (100 nmol) inhibited TPA-induced epidermal, upper dermal and deep dermal
inflammation by 71%, 45% and 22%, respectively, at 24 h (n = 3, P < 0.05). TPA-induced epidermal
hyperplasia was inhibited by
SCH 47112 (400 nmol) by 38% at 48 h (n = 3, P < 0.05). In addition, in cultured human keratinocytes,
SCH 47112 inhibited TPA induction of
transglutaminase. I
protein, which catalyzes the formation of crosslinked envelopes. These results indicate that
SCH 47112 exhibits
biological activity, inhibiting TPA-induced changes in hairless mouse skin in vivo and cultured human keratinocytes in vitro, and suggest that PKC inhibitors may have a therapeutic role in inflammatory
skin diseases.